Pfizer Generates $3.5b in Q1 & Forecasts $26 billion from COVID-19 Vaccine in 2021

Pfizer Generates $3.5b in Q1 & Forecasts $26 billion from COVID-19 Vaccine in 2021

Those pharmaceutical companies that develop safe and effective vaccines and therapies during the pandemic receive windfall profits as Pfizer now has reported that the COVID-19 vaccine originally developed in Germany by BioNTech called BNT162b2 (trade name Comirnaty) has generated $3.5 billion in the first three months of 2021, representing nearly 25% of its overall turnover, the company declared, before its earning call today. Now the American pharmaceutical giant expects vaccine revenues to total $26 billion in 2021, a massive injection of new revenues not anticipated just a year ago. These forecasts are based on a number of inked deals since April, securing up to 1.6 billion doses to be delivered in 2021.

And now the company’s CEO Albert Bourla declared last month that its “likely” that a third dose of the COVID-19 vaccine will be needed, probably 12 months after full (2 dose) vaccination. He suggested that its possible that an annual vaccination will be likely against the coronavirus.

Responses